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Abstract
Background: India carries one quarter of the global burden of multi-drug resistant TB (MDR-TB) and has an estimated 2.5
million people living with HIV. Despite this reality, provision of treatment for MDR-TB is extremely limited, particularly for
HIV-infected individuals. Me ´decins Sans Frontie `res (MSF) has been treating HIV-infected MDR-TB patients in Mumbai since
May 2007. This is the first report of treatment outcomes among HIV-infected MDR-TB patients in India.
Methods: HIV-infected patients with suspected MDR-TB were referred to the MSF-clinic by public Antiretroviral Therapy
(ART) Centers or by a network of community non-governmental organizations. Patients were initiated on either empiric or
individualized second-line TB-treatment as per WHO recommendations. MDR-TB treatment was given on an ambulatory
basis and under directly observed therapy using a decentralized network of providers. Patients not already receiving ART
were started on treatment within two months of initiating MDR-TB treatment.
Results: Between May 2007 and May 2011, 71 HIV-infected patients were suspected to have MDR-TB, and 58 were initiated
on treatment. MDR-TB was confirmed in 45 (78%), of which 18 (40%) were resistant to ofloxacin. Final treatment outcomes
were available for 23 patients; 11 (48%) were successfully treated, 4 (17%) died, 6 (26%) defaulted, and 2 (9%) failed
treatment. Overall, among 58 patients on treatment, 13 (22%) were successfully treated, 13 (22%) died, 7 (12%) defaulted,
two (3%) failed treatment, and 23 (40%) were alive and still on treatment at the end of the observation period. Twenty-six
patients (45%) experienced moderate to severe adverse events, requiring modification of the regimen in 12 (20%). Overall,
20 (28%) of the 71 patients with MDR-TB died, including 7 not initiated on treatment.
Conclusions: Despite high fluoroquinolone resistance and extensive prior second-line treatment, encouraging results are
being achieved in an ambulatory MDR-T- program in a slum setting in India. Rapid scale-up of both ART and second-line
treatment for MDR-TB is needed to ensure survival of co-infected patients and mitigate this growing epidemic.
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Introduction
In India, multidrug-resistant tuberculosis (MDR-TB) is estimat-
ed to account for 2.3% (95% Confidence Intervals (CI): 1.8–2.8) of
new cases and 17.2% (95% CI: 14.9–19.5) of previously treated
TB cases [1]. Reports from several states suggest that the
prevalence of MDR-TB among previously-treated patients varies
around the country, with values ranging from 7% to over 50% [2–
5]. A relatively recent publication from Mumbai showed a high
MDR-TB prevalence of 24% and 41% among new and re-
treatment cases respectively [6]. WHO estimate the number of
MDR-TB cases in 2009 in India at 99,000 (79,000–120,000)
which represents approximately 25% of the global burden of
MDR-TB [1].
Infection with Human Immunodeficiency Virus (HIV) further
complicates the management of MDR-TB. India has the third
highest HIV burden in the world with an estimated 2.5 million
people living with HIV/AIDS in 2006 [7]. Data from other
settings suggest that mortality from MDR-TB in HIV-infected
patients is extraordinarily high, particularly within the first 30 days
after diagnosis [8].
Systematic reviews have shown that few studies describe MDR-
TB treatment outcomes from high HIV prevalence settings and
that HIV status is often inconsistently reported [9,10]. Although
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has been shown to improve outcomes in co-infected patients
[9,10,11], treatment of MDR-TB in HIV-infected patients
remains a challenge. Patients are required to take large numbers
of pills each day and there is the potential for additive side effects
and drug interactions between antiretroviral agents and second-
line anti-tuberculosis drugs [12].
Overall, there is a serious deficiency in reports describing
treatment of MDR-TB in HIV-infected patients, especially in
programmatic settings in resource-constrained countries. A recent
study from Lesotho showed that starting early empirical treatment
for suspected MDR-TB patients using a community-based
treatment approach in mainly HIV-infected adults resulted in
high culture conversion, although significant mortality remained
[13].
While Mumbai has a widely accessible DOTS program in place
under the Revised National Tuberculosis Control Program
(RNTCP) for treatment of drug-susceptible tuberculosis, treatment
for drug-resistant TB was, until recently, only available through
the private sector. As a result, MDR-TB treatment has often been
administered in a chaotic, unregulated manner using non-pre-
qualified anti-TB drugs and at prohibitive prices for the large
majority of patients. Given the large MDR-TB disease burden,
there is an urgent need to scale up appropriate treatment for
MDR-TB in India and in order to achieve this, a decentralized
approach may be most appropriate. Special focus should be on
early diagnosis and treatment initiation, particularly among HIV-
infected populations.
In February 2006, Me ´decins Sans Frontie `res (MSF) started an
HIV project in Mumbai, offering care and treatment to people
living with HIV unable to access the public system or who could
not obtain appropriate ART regimen, including second-line
antiretroviral drugs. MSF has been treating MDR-TB among
HIV-infected individuals in this project since May 2007. MDR-
TB treatment subsequently became available in the public sector
in Mumbai in late 2010.
This report aims to describe patient and treatment outcomes in
a cohort of HIV/MDR-TB co-infected patients treated on an
outpatient basis, in an urban, overpopulated slum setting in
Mumbai, India. To our knowledge, this is the first analysis of
MDR-TB patient outcomes in HIV-infected patients in India.
Methods
Study design
This was a prospective, observational cohort study using data
routinely collected at each consultation and entered into an
electronic database.
Setting and study population
MSF has been operating a clinic in Khar, a suburb in Mumbai,
India since 2006. It is specialized in HIV care and provides
treatment free of charge to patients referred by accredited public
and public-private Antiretroviral Treatment Centers (ART
Centers) from the greater Mumbai area and by a network of
community non-governmental organizations (NGOs). The great
majority of patients are slum-dwellers.
An MDR-TB component was added to the HIV treatment
program in May 2007. MDR-TB care and treatment is offered on
an outpatient-clinic basis. In general, patients have been referred
to the clinic for evaluation of confirmed or suspected MDR-TB, by
clinicians working in the Ministry of Health and Family Welfare
network of ART centers, and by private physicians or community
NGOs.
All HIV-infected patients with bacteriologically confirmed
MDR-TB or those suspected to have MDR-TB, based on clinical
findings and TB treatment history but without bacteriological
confirmation who were followed up in the clinic between May
2007 and May 2011 were included in this study.
Mycobacterial Culture and Drug Susceptibility Testing
(DST)
HIV-infected patients with symptoms suggestive of TB or any
patient referred to the clinic with MDR-TB suspicion were
screened with two sputum samples for acid-fast bacilli (AFB) by
sputum smear microscopy and two for AFB culture. Culture and
DST was performed using BACTEC MGIT 960 system (Becton-
Dickson, Sparks, Maryland, USA). Drug susceptibility testing
(DST) was performed on all culture positive isolates against four
first-line TB drugs: isoniazid, rifampicin, ethambutol and
streptomycin and four second-line drugs (kanamycin, ethionamide,
para-aminosalicylic acid (PAS) and ofloxacin) using World Health
Organization (WHO) approved guidelines for drug concentra-
tions. Samples were processed in the Laboratory Medicine
Department of the P. D. Hinduja National Hospital & Medical
Research Centre, Mumbai, which is accredited by the Revised
National Tuberculosis Control Program (RNTCP) and the
College of American Pathologists (CAP) to perform first line
DST to Streptomycin, isoniazid, rifampicin and ethambutol. For
the phenotypic second line DST, the laboratory was performing
internal quality control weekly and twice a year inter –laboratory
external quality control with CAP accredited laboratories. Some
patients (approximately ten) brought DST results from various
private TB laboratories in Mumbai showing resistance to isoniazid
and rifampicin. Patients were started on treatment with second-
line TB drugs, after baseline investigations and counselling were
completed, and were asked to produce sputum for culture and
DST before starting treatment.
Treatment protocol
The clinic treatment protocols follow WHO international
guidelines [12]. Whenever possible, an individualized treatment
regimen was designed for each patient, based on the first and
second line DST results and on patient’s treatment history. A
standardized treatment regimen was used for empiric treatment in
those patients who required prompt treatment initiation due to the
severity of their disease.
The standardized regimen included six drugs: pyrazinamide,
capreomycin, moxifloxacin, ethionamide, cycloserine and PAS.
The standardized regimen was modified once the DST results
became available. The same standardized regimen was continued
for patients with unconfirmed MDR-TB, diagnosed on clinical
grounds and treatment history. All TB drugs were dosed according
to bodyweight. Dosing and drugs were also changed in response to
severe adverse effects. The severity of adverse events was defined
by laboratory criteria (whenever quantifiable) or based on effect on
patient tolerance and adherence. Adverse events were aggressively
managed and regimen modification was done as last resort.
Patients, unless already on ART, were started on antiretroviral
drugs as soon as they were tolerating second-line TB drugs,
irrespective of CD4 cell count. Two nucleoside reverse transcrip-
tase inhibitors and one non-nucleoside reverse transcriptase
inhibitor were used for patients being prescribed 1
st line ART,
while patients in need of 2
nd line ART (mostly patients with
virological failure, defined as two consecutive, detectable HIV
RNA viral loads) received a protease inhibitor-based regimen [14].
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Patients in stable clinical condition were started on MDR-TB
treatment on an ambulatory basis. Patients were evaluated by a
multidisciplinary team of trained physicians, nurses, social workers
and psychologists. The same team provided care and treatment for
HIV in a ‘‘one stop’’ service. The attending physician examined
patients clinically at least once a week in the first month of
treatment and once or twice a month thereafter, depending on the
patient’s clinical condition. Special attention was given to identify
gastro-intestinal adverse events, hearing loss or tinnitus (including
monitoring audiograms), depressive or psychotic symptoms, and
signs of hypothyroidism. Sputum smear and culture were repeated
monthly until the end of the intensive treatment phase and every
other month during the continuation phase. Chest X-ray was not
routinely used for treatment monitoring.
In the very early stages of the program, a self-administered
treatment strategy was tried, but the strategy soon shifted to twice-
daily directly observed treatment (DOT). DOT was planned to be
available no more than 10 minutes walking distance from patients’
homes. This was possible thanks to a community network of
public/private health structures and non-governmental organiza-
tions (NGOs) that acted as DOT providers. These included public
health posts, private practitioners and local NGOs, the great
majority of which were based in slums.
DOT providers were trained to provide DOT, administer
injections and monitor for adverse effects. MSF supplied the providers
with second line TB drugs, materials to give injections, masks and N95
respirators, and training on infection control. Each DOT provider was
supervised weekly by phone and monthly by an MSF staff visit.
Patients went to the DOT provider daily to receive TB treatment and
monthly to the MSF clinic for medical and psychosocial follow-up.
Patients who were unable to ambulate or were otherwise
unstable clinically were admitted to a charity hospital under the
supervision of the MSF clinical team. Patients were also admitted
if they experienced severe adverse effects or other clinical
complications precluding outpatient management. Treatment
was continued for a minimum of 18 months total duration,
including a minimum of 6 months intensive treatment with the
injectable agent. All treatment was provided free of charge.
Data collection
Demographic and clinical information were systematically
recorded on standardized clinical files designed specifically for
the program. Information on all patients was prospectively
collected and entered into an electronic database. Information
on HIV and antiretroviral treatment was collected in the same
patient file but entered in a separate database. Each patient had a
unique identification code that was used in both databases.
Trained personnel extracted clinical, treatment, and laboratory
data from individual patient records regularly and entered them
into both databases. A full time data manager routinely checked
data entry for accuracy and completeness.
Ethics
The study protocol was approved by the Independent Ethics
Review Board of Me ´decins Sans Frontie `res, Geneva, Switzerland.
As this was a study of routinely collected monitoring data,
informed consent from the patients was not obtained. The named
ethics committee specifically waived the need for consent.
Statistical methods
Data from all patients diagnosed with MDR-TB between May
2007 and May 2011 were used in the analyses. Patient
characteristics at admission in the MDR-TB program and their
status at the end of the study period were summarized using
descriptive statistics. Kaplan-Meier analysis was performed to
assess survival probability. Patient follow-up ended when an
outcome was recorded, or censored on May 15, 2011. Possible
outcomes, defined according to WHO guidelines, included: cure,
treatment completed, death, default, transfer out, treatment
failure, and ‘alive and on treatment’ [12,15]. Microsoft Excel
and SPSS (version 16.0, Chicago, IL) were used for analysis.
Results
Patient characteristics
Between May 2007 and April 2011, 71 patients were diagnosed
with MDR-TB (57 (80%) bacteriologically confirmed and 14
(20%) unconfirmed) and registered in the MSF clinic (Figure 1).
Twelve of these patients never started MDR-TB treatment: seven
of them died before treatment initiation, two patients refused
treatment after counselling, one patient was lost to follow-up and
for two patients second-line anti-TB treatment was not considered
medically indicated: one patient dramatically improved on first-
line anti-TB treatment while waiting for the DST results (including
culture conversion) and for the second patient there were no
therapeutic options available other than palliative care (patient
susceptible only to PAS). All of the remaining 59 patients started
treatment with second-line TB drugs. One of the suspected
patients was subsequently found to be infected with pan-
susceptible M. tuberculosis strains after three months of second-line
treatment. This patient was switched to first-line treatment and
excluded from the outcome analysis (Figure 1). Baseline charac-
teristics of the patients are shown in Table 1.
Tuberculosis clinical characteristics and treatment history
Twenty-five (43%) of the 58 patients were sputum AFB-positive
and 47(81%) were culture positive before starting treatment. Ten
patients were smear- and culture-negative, four of whom had
extra-pulmonary TB. Overall, 50 patients (86%) had pulmonary
TB, seven of whom were diagnosed with both pulmonary and
extra-pulmonary TB (three abdominal, three cerebral and one
vertebral TB). Eight patients (14%) were diagnosed as having only
extra-pulmonary TB, three of whom had signs of TB at more than
one site. Among the patients with pulmonary TB, 39 were
confirmed and 11 remained unconfirmed, while 5 extra
pulmonary TB patients were bacteriologically confirmed and
three were started on treatment based on clinical condition and
TB treatment history (Table 1).
All but five patients (91%) had received previous TB treatment,
half of them in the public sector and half of them in the private or
both sectors. Strikingly, half of these patients had a history of
previous exposure to second-line TB drugs, most commonly
fluoroquinolones. This is reflected in the 40% ofloxacin resistance
among bacteriologically confirmed cases in this patient cohort
(Table 2). No MDR-TB patients were diagnosed with resistance to
second-line injectable drugs. Three patients (6% among bacteri-
ologically confirmed) were diagnosed with extensively drug-
resistant TB (XDR-TB).
HIV clinical characteristics and treatment history
The median CD4-count at the time of MDR-TB treatment
initiation was 135 cells/ml (IQR: 85–193). Most patients, especially
during the later years, were registered in the clinic at the time of
diagnosis of MDR-TB. Thirty-seven patients (64%) were on ART
before a diagnosis of MDR-TB was made. Eight patients were on
second line ART. Three patients never started ART: two migrant
MDR-TB Treatment Outcomes in Indian HIV+ Patients
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and one patient who was about to start at the time of the analysis.
Treatment outcomes
Among the 23 patients initiated on treatment prior to May 2009
(24 months of follow-up), seven patients (31%) were cured, four
(17%) have completed treatment, four patients (17%) died, six
defaulted (26%) and two patients (9%) failed treatment.
Among these 23 patients, eight TB strains were resistant to
ofloxacin ; two of them completed treatment, one died and five
defaulted. Patients without fluoquinolone resistance (15) were
more likely to be cured and less likely to default than patients with
resistance to fluoquinolones (p,0.05). The two patients who failed
treatment had no baseline resistance to ofloxacin or to injectable
drugs.
Overall among the total 58 patients, eight patients (14%) were
cured, five (9%) completed treatment, 13 patients (22%) died,
seven defaulted (12%), two patients (3%) failed treatment and 23
patients (40%) were alive and in treatment at the end of the
observation period.
Out of 25 patients with a positive sputum smear at baseline,
thirteen (52%) achieved sputum smear conversion in the first two
to four months of treatment (median 2 months). Similar rates of
culture conversion were observed. Out of the 44 patients with a
baseline positive culture, 23 (52%) achieved culture conversion in
the first four months of treatment.
Mortality, causes of death and loss to follow-up
Survival curves for the 58 patients who started on treatment are
shown in Figures 2a and 2b. Survival is measured in months after
starting MDR-TB treatment. Crosses indicate censored patients.
The probability of survival at 24 months of treatment was 0.75.
Death occurred after a median of 27 days in treatment (range
1–229 days). Causes of death for the 13 patients who died included
four deaths not related to TB or treatment (one head injury, one
renal failure, one diabetic ketosis and one HIV wasting syndrome).
Among the seven patients who did not complete treatment, one
was a Nepalese migrant worker who decided to repatriate, one a
sex worker who had problems to access the clinic and one a 16
year old adolescent who refused to continue after 15 months of
treatment despite the absence of adverse events and receiving
intensive counseling and psychosocial support. Two patients
diagnosed with XDR-TB were also lost to follow-up despite
efforts from the psychosocial team to trace them. Two more
patients had no apparent reason to default.
Adverse events
Adverse events associated with second line DR-TB treatment
are summarized in Table 3.
The most common adverse drug reactions were related to
abnormal thyroid function (assessed by TSH, T3 and T4
measurements) due to PAS and/or ethionamide, and hypokalae-
mia, due to the aminoglycosides and capreomycin. Drug dosages
had to be adjusted in two patients with renal impairment. For
patients with psychosis/depression, seizures, hearing loss and
tendonitis, the drugs assumed to be responsible were discontinued.
All other events were managed symptomatically and without
physician-directed discontinuation of therapy.
Immunological recovery
Out of 58 patients who started TB treatment, 37 were already
on ART, 18 started ART during TB treatment and three never
started as previously described. Figure 3 shows the CD4-count
evolution over time, under MDR-TB treatment and ART: the
median CD4-count increased to 224 cells/ml (IQR: 135–311) and
331 cells/ml (IQR: 247–367) after one and two years of treatment
respectively.
Discussion
This is, to our knowledge, the first report on MDR-TB
treatment outcomes from a cohort of HIV-infected patients in
India [9,10]. Despite India’s large burden of MDR-TB there are
discouragingly few reports of successful treatment programs from
the sub-continent [16]. A recent study from the Tuberculosis
Research Center in Chennai, reported good MDR-TB treatment
outcomes in a cohort of 38 patients, however, HIV-infected
patients were excluded from the study [17]. Our study of a
Mumbai cohort of HIV-infected patients only, shows encouraging
results in terms of survival, cure rates, culture conversion and
immunological recovery, especially considering high rates of
fluoroquinolone resistance and previous second-line treatment in
this cohort. MDR-TB treatment programs with largely HIV-
negative patients have reported cure rates and death rates of 61–
77% and 5–19% respectively [9,10,18–21]. The early results of a
treatment program in Lesotho [13], however, showed that MDR-
TB treatment outcomes in HIV-infected cohorts were likely to be
significantly worse: overall, 29% of patients died. There was a
trend towards poorer outcomes in HIV-infected individuals, with
significant mortality in the first few weeks after DR-TB treatment
initiation; these results were consistent with previous studies
Figure 1. Flowchart of patients with MDR-TB/HIV co-infection
enrolled in care between 2006 and 2011, Mumbai, India.
doi:10.1371/journal.pone.0028066.g001
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Started on MDR-TB treatment Total
Number of patients enrolled 59 71
Confirmed 45 57
Unconfirmed 14 14
Demographics
Age in years, median (min-max) 35 (11–61) 35 (11–61)
Women, n (%) 26 (44) 35 (49)
Social Stratum n (%)
Lower 42 (71.2) 46 (64.8)
Middle 11 (18.6) 12 (16.9)
Upper 2 (3.4) 2 (2.9)
Unknown 4 (6.8) 11 (15.4)
TB History & clinical presentation Co-infected patients who started MDR-TB treatment (n=58)
Previous TB treatment n (%)
Public sector 26 (44.8)
Private sector 9 (15.5)
Both sectors 16 (27.6)
No previous treatment 5 (8.6)
Unknown 2 (3.4)
Exposed to 2nd line anti TB drugs
Yes 26 (44.8)
NO 28 (48.3)
Unknown 4 (6.9)
Sputum or other sample smear at treatment initiation n (%)
Positive 25 (43.1)
Negative 33 (56.9)
Sputum or other sample culture at treatment initiation n (%)
Positive 47 (81)
Pulmonary/Extra pulmonary 38/9
Negative 11 (20.7)
Pulmonary/Extra pulmonary 8/3
Tuberculosis site n (%)
Pulmonary 50 (86.2)
confirmed/suspected 39/11
Extra pulmonary 8 (13.8)
confirmed/suspected 5/3
HIV History & clinical presentation Co-infected patients who started MDR-TB treatment (n=58)
Median (IQR) CD4-count at MDR-TB treatment initiation (cells/ml) 135 (85–193)
ART treatment history n (%)
On ART before anti-MDR-TB 37 (63.8)
On ART after anti-MDR-TB 18 (31)
No ART 3 (5.2)
Median time from MDR-TB treatment start to ART initiation : months (IQR) 1.1 (1.1–4.7)
ART n (%)
First line 45 (77.6)
Second line 8 (13.8)
doi:10.1371/journal.pone.0028066.t001
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negative patients with drug-susceptible TB [22,23]. We observed
lower mortality rates in our cohort of co-infected patients;
however, the high defaulter rate recorded may mask unreported
mortality. The high early mortality seen in the cohorts of HIV-
infected patients argues strongly for early initiation of both ART
and second-line TB drugs.
In Mumbai, MDR-TB treatment was until recently (July 2010)
only available through an unregulated, private health sector [16].
However, the private sector does not generally consider the risk of
resistance amplification or the ongoing challenges of adherence to
a very long and costly treatment regimen fraught with a high pill
burden and significant adverse events. Private physicians rarely (if
ever) use DOT as treatment strategy. The particular setting of
Mumbai, a mega-metropolis where the marginalised may have
inadequate nutrition, rudimentary sanitation and poor home-
ventilation is particularly challenging. Difficult transportation and
an extremely mobile population, further complicates the manage-
ment and the follow-up of these patients. Thirty-seven percent of
the patients in our cohort had already received second-line TB
Table 2. Resistance patterns in a Mumbai cohort of HIV/MDR-TB co-infected patients.
Drug resistance profile
No previous TB treatment or first line
treatment only Previously exposed to second line drugs
Suspected MDR-TB 6 7
MDR, but no second line resistance
HR 1 1
HR+other first-line 8 7
MDR with second line resistance (but not XDR)
HR+Ofx 7 11
HR+second-line injectable 0 0
HR+Group 4 drugs 6
+ 2
XDR 2 0
+including one strain with isoniazid susceptibility.
R: Rifampicin, H: Isoniazid, Ofx: ofloxacin.
doi:10.1371/journal.pone.0028066.t002
Figure 2. Time to death under MDR-TB treatment.
doi:10.1371/journal.pone.0028066.g002
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to their medical records and referral notes (when available), they
were often on erratic regimes, under-dosed and had their
treatment interrupted as they could not afford the high cost of
second line anti-TB drugs for long periods of time [24,25].
The Mumbai MSF clinic has been trying to address these MDR-
TB challenges since the program started in 2007. The outcomes
recordedsofarintheprogramdemonstrate thefeasibilityoftreating
HIV/MDR-TB co-infected patients in such a setting. Given the
high rate of resistance to fluoroquinolones in India [4,26] and
erratic previous treatment for many of the patients the outcomes are
reasonable. We suggest that the following factors contributed to
these results: first, all patients received DOT thanks to a network of
individual DOT providers, allowing each patient to easily access
care within walking distance from his/her home. By moving
treatment into the community, it was possible to overcome
problems of patient access to clinics. Second, the monitoring plan
for early identification of adverse events, that included systematic
clinical and laboratory assessment, and the availability of ancillary
drugs helped to promptly diagnose and appropriately manage
adverse drug effects. Third, therapy followed internationally
recommended guidelines with maximally effective drug combina-
tions, based on DST, and at the highest recommended doses [12];
this likely reduced the risk of treatment failure and amplification of
resistance. Fourth, psychosocial support was given to all patients
with monthly home visits and specific support tools were developed.
A multidisciplinary team (doctors, nurses, counsellors, psychologists)
was essential to manage adherence challenges and psychological
issues related to the disease and its treatment, stigma and isolation.
Fifth, TB and HIV care were fully integrated: patients received
treatment for both conditions in the same clinic as part of a ‘‘one-
stop service’’. This increased convenience for patients, saved time
and travel expenses, and facilitated detection of drug interactions
and adverse events. Moreover, the integrated approach has
broadened expertise in the clinic team on the management of co-
infected patients. Sixth, ambulatory treatment and follow-up may
have reduced default and the risk of re-infection during hospital-
ization [27].
Table 3. Adverse drug reactions in MDR-TB/HIV co-infected patients under treatment.
Reactions n (%) Regimen change (n)
Hypothyroidism/Altered thyroid function tests 19 (33) 0
Hypokalemia 8 (14) 0
Gastrointestinal symptoms 7 (12) 0
Psychosis 7 (12) 3
Loss of hearing 5 (9) 4
Tendonitis 3 (5) 3
Renal impairment 2 (3) 0
Depression 2 (3) 1
Peripheral Neuropathy 2 (3) 0
Arthralgia 2 (3) 0
Abscess at injection site 2 (3) 0
Seizures 1 (2) 1
Vertigo/ataxia 1 (2) 0
doi:10.1371/journal.pone.0028066.t003
Figure 3. CD4 evolution over time in MDR-TB/HIV co-infected patients under ART and MDR-TB treatment, Mumbai, India.
doi:10.1371/journal.pone.0028066.g003
MDR-TB Treatment Outcomes in Indian HIV+ Patients
PLoS ONE | www.plosone.org 7 December 2011 | Volume 6 | Issue 12 | e28066A large investment has been made in the clinic in TB infection
control measures that prevent transmission of TB. A comprehen-
sive infection control plan was designed and implemented,
including environmental and administrative measures and per-
sonal protective equipment for the clinic staff. The clinic defined
specific MDR-TB days, carefully organized the spacing between
MDR-TB consultations, improved ventilation in consultations
rooms, corridors and waiting areas and trained the staff in
prevention of TB transmission. An infection control committee
was established and it is now planned to expand infection control
measures to the community and household level through
innovative, small-scale interventions.
However, several challenges remain in this program. The high
pre-treatment and early mortality rates highlight the need for
intensive case finding strategies, rapid diagnosis and initiation of
DR-TB treatment to reduce mortality and improve outcomes.
Late referral to the clinic and advanced disease may partly explain
these high rates. Studies from HIV programs have shown than
even if excellent outcomes can be achieved and maintained among
patients receiving antiretroviral therapy, program outcomes such
as high pre-treatment mortality and pre-treatment loss-to-follow-
up rates remain largely unreported [28,29]. Similarly, failure to
initiate therapy and default from treatment rates were high in this
cohort, despite the provision of counselling and other psychosocial
support. Our data suggests that default from treatment may be
lower in more recent cohorts. While the MSF clinic reports very
low loss-to-follow-up rates among non-MDR-TB patients on ART
(,3%) it is disappointing that the overall rate was 26% for the co-
infected patients on treatment. While there are known challenges
related to the management of co-infection, several measures may
have to be urgently taken to analyze and address this important
issue. In our clinic, for example, we identified important gaps in
patient support tools and interventions, including lack of adequate
emotional and psychosocial support as well as limited access to
mental health services. We have also noticed that patients referred
to our clinic from the private sector have already been on various
treatment regimens for long time periods and often experience
treatment fatigue. Support from families is also reported to wane
over time.
In this Mumbai cohort, several patients were started empirically
on second-line drugs before DST results were available, based on
WHO recommendations [30]. The RNTCP in India is particu-
larly concerned with empirical treatment and strongly discourages
clinicians to initiate treatment without laboratory confirmation.
Considering the challenges with the unregulated private sector and
the lack of trained and experienced clinicians in the management
of MDR-TB in the Indian public sector, these concerns may be
well justified. Ideally rather than relying on empiric treatment,
efforts should be directed at introducing more rapid diagnosis that
will offer both bacteriological confirmation and result in more
rapid treatment initiation. The recently approved Xpert MTB/
RIF (Xpert) test, has been demonstrated to be feasible in different
high burden settings and has the potential to dramatically improve
case detection for drug-resistant TB [31,32]. Moreover, a recent
study suggested that Xpert MTB/RIF shows good potential in the
diagnosis of extrapulmonary TB and this is relevant for HIV-
infected individuals [33].
In Mumbai, a community-based model of MDR-TB treatment
was found to be feasible, as has been shown in other countries
[13,18,27,34–36]. DOT providers at the community level were
trained to provide injections, observe pill-taking, monitor for
adverse effects and support and refer patients. Adverse events
occurred relatively often in this cohort, similar to a cohort from
Lesotho [13]. We recorded relatively high rates of hypothyroidism
and psychosis. However, with aggressive management of side
effects, alterations to the TB regimen were rarely necessary.
There are some limitations to our analysis. Overall, the size of
the cohort is relatively small and therefore does not allow definitive
conclusions to be drawn regarding factors that may contribute to
patient outcomes, particularly the high pre-treatment mortality
and default from treatment. Further research aims to investigate
these areas in more detail.
However, to date, there is a dearth of documented program
experiences from resource-constrained settings treating co-infected
patients; the global cohort of HIV/MDR-TB co-infected patients
being treated is still discouragingly small.
Despite these limitations, and despite high fluoroquinolone
resistance and extensive prior second-line treatment, this report
provides encouraging evidence of the feasibility of offering
ambulatory MDR-TB treatment in HIV-infected populations,
even in a challenging, urban, resource-constrained setting. This
community-based treatment model may have been successful in
reducing mortality of HIV/MDR-TB co-infected patients. Rapid
scale-up of both antiretroviral therapy and second line treatment
for MDR-TB is needed to ensure survival of co-infected patients,
and control the emerging epidemic of drug resistant TB in
Mumbai.
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